GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

It stands out in a region where Amish farms and hills covered with second-growth red-oak woods, parks, and hiking trails ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

Several companies such as Shriram Finance, Symphony, etc. will be in focus today on account of corporate actions.

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...